Get the Stockscreener App
24.19
2.30%
-0.57
After Hours:
24.45
0.26
+1.07%
Uniqure Nv stock is traded at $24.19, with a volume of 670.56K.
It is down -2.30% in the last 24 hours and up +36.05% over the past month.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
See More
Previous Close:
$24.76
Open:
$24.95
24h Volume:
670.56K
Relative Volume:
0.22
Market Cap:
$1.53B
Revenue:
$16.10M
Net Income/Loss:
$-198.97M
P/E Ratio:
-6.9494
EPS:
-3.4809
Net Cash Flow:
$-183.99M
1W Performance:
-10.57%
1M Performance:
+36.05%
6M Performance:
-13.02%
1Y Performance:
+58.83%
1-Day Range:
$24.16
$25.54
1-Week Range:
$24.01
$27.49
52-Week Range:
$8.73
$71.50
Uniqure Nv Stock (QURE) Company Profile
Name
Uniqure Nv
Sector
Industry
Phone
1-339-970-7000
Address
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure Nv
|
24.19 | 1.56B | 16.10M | -198.97M | -183.99M | -3.4809 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Uniqure Nv Stock (QURE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-26 | Upgrade | Mizuho | Neutral → Outperform |
| Mar-09-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-09-26 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-03-26 | Downgrade | Mizuho | Outperform → Neutral |
| Mar-03-26 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-02-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Mar-02-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-24-26 | Initiated | Wolfe Research | Peer Perform |
| Jan-28-26 | Initiated | Barclays | Equal Weight |
| Nov-04-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-14-25 | Upgrade | Mizuho | Neutral → Outperform |
| Apr-01-25 | Resumed | Chardan Capital Markets | Buy |
| Dec-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Feb-29-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-19-23 | Downgrade | Mizuho | Buy → Neutral |
| Mar-17-22 | Upgrade | UBS | Neutral → Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-01-21 | Upgrade | Mizuho | Neutral → Buy |
| Jan-07-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-24-20 | Initiated | H.C. Wainwright | Buy |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-09-20 | Initiated | Jefferies | Buy |
| Nov-04-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-20 | Initiated | Raymond James | Strong Buy |
| Jul-31-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-25-20 | Downgrade | Mizuho | Buy → Neutral |
| Jun-25-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-25-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-03-19 | Initiated | Cowen | Outperform |
| Dec-03-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Outperform |
| Oct-11-19 | Initiated | Stifel | Buy |
| Sep-25-19 | Initiated | Bernstein | Outperform |
| Sep-12-19 | Initiated | Mizuho | Buy |
| Jul-30-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
View All
Uniqure Nv Stock (QURE) Latest News
What Just Happened with uniQure's Earnings and FDA Update - Kavout
What Caused uniQure's Dramatic Stock Plunge - Kavout
Numero AI and Royu Merge to Redefine How Finance Teams Operate - Benzinga
Mizuho downgrades UniQure NV (QURE) - MSN
UniQure stock falls after FDA's notes on pre-application of AMT-130 - MSN
Considering Uniqure NV (QURE) Stock? Read the AMT-130 Message - Insider Monkey
Uniqure NV at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Price-Driven Insight from (QURE) for Rule-Based Strategy - Stock Traders Daily
Huntington's Disease Pipeline 2026: Therapies Under - openPR.com
UniQure NV (QURE) price target decreased by 26.57% to 37.82 - MSN
Mizuho maintains uniQure NV (QURE) outperform recommendation - MSN
QURE stock just shot up 8%uniQure’s much-talked-about Huntington’s disease therapy gets a UK boost - MSN
UBS Group AG Buys 286,465 Shares of uniQure N.V. $QURE - MarketBeat
uniQure N.V.Ordinary Shares (NQ: QURE - The Chronicle-Journal
RTW Investments and R. Wong report 2.59M shares in uniQure (NASDAQ: QURE) - Stock Titan
Tejara Capital Ltd Takes $1.01 Million Position in uniQure N.V. $QURE - MarketBeat
Q4 2025 Uniqure NV Earnings Call Transcript - GuruFocus
Uniqure NV at TD Cowen Healthcare Conference Transcript - GuruFocus
What Triggered uniQure's Sudden Stock Plunge - Kavout
uniQure NV(QURE) Stock Options Chain | Quotes & News - Moomoo
uniQure N.V. (NASDAQ: QURE) Long Term Investor Alert: Investigation of potential Wrongdoing - openPR.com
Makary exit may temporarily lift biotech sentiment but FDA leadership vacuum looms - marketscreener.com
Is uniQure N.V. (QURE) A Good Stock To Buy Now? - Insider Monkey
Uniqure Insider Sold Shares Worth $1,127,500, According to a Recent SEC Filing - marketscreener.com
uniQure (QURE) CMO sells 45,000 shares under 10b5-1 plan, exercises options - Stock Titan
uniQure NV | SCHEDULE 13G: Others - Moomoo
State Street (QURE) affiliates disclose 3.6% ownership, 2.26M shares - Stock Titan
UniQure Q1 Earnings Review: Limited Progress With FDA, But UK Approval In Play - Seeking Alpha
FDA's Makary On Brink: Why Biotech And Pharma Investors Shouldn't Panic (Or Celebrate) - Seeking Alpha
Nan Fung Trinity HK Ltd. Purchases New Holdings in uniQure N.V. $QURE - MarketBeat
UniQure (QURE) files Form 144: 45,000 shares, vested and exercised stock listed - Stock Titan
uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Have Been Cutting Their Estimates - simplywall.st
uniQure N.V. (NASDAQ:QURE) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - Yahoo Finance
UniQure plans UK AMT-130 MAA submission in Q3 as it expects cash runway into H2 2029 - MSN
uniQure N.V. (QURE) Stock Analysis: A Potential Upside of 64% Amidst Promising Gene Therapy Innovations - DirectorsTalk Interviews
(QURE) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
UniQure (QURE) Q1 2026 Loss Of US$53.5m Tests Bullish Growth Narrative - Sahm
RBC Capital Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Cuts Target Price to $50 - 富途牛牛
uniQure NV | SCHEDULE 13G/A: Others - Moomoo
FMR LLC lists 1.74M UNIQURE shares (2.8%) — UNIQURE (NASDAQ: QURE) - Stock Titan
Transcript: uniQure Q1 2026 Earnings Conference Call - Sahm
A Quick Look at Today's Ratings for UniQure NV(QURE.US), With a Forecast Between $25 to $37 - 富途牛牛
MSN Money - MSN
Stifel Maintains UniQure NV(QURE.US) With Buy Rating, Announces Target Price $28 - 富途牛牛
TD Cowen Maintains UniQure NV(QURE.US) With Buy Rating - 富途牛牛
uniQure Q1 Earnings Call Highlights - Yahoo Finance
UniQure N.V. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
uniQure Releases Q1 2026 Financial Results - AlphaStreet
UniQure Shares Fall After Q1 Loss Widens - marketscreener.com
Uniqure Nv Stock (QURE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Uniqure Nv Stock (QURE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Abi-Saab Walid | Chief Medical Officer |
May 08 '26 |
Sale |
25.06 |
45,000 |
1,127,500 |
169,669 |
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):